CA Patent

CA3207235A1 — Concentrated liquid gel formulations containing naproxen salts

Assigned to Bayer Healthcare LLC · Expires 2022-07-14 · 4y expired

What this patent protects

This disclosure is in the field of mini-softgel capsules, particularly softgel capsules containing naproxen salt as an active ingredient. It relates generally to softgel capsules containing high concentration formulations of naproxen sodium.

USPTO Abstract

This disclosure is in the field of mini-softgel capsules, particularly softgel capsules containing naproxen salt as an active ingredient. It relates generally to softgel capsules containing high concentration formulations of naproxen sodium.

Drugs covered by this patent

Patent Metadata

Patent number
CA3207235A1
Jurisdiction
CA
Classification
—
Expires
2022-07-14
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Healthcare LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.